The use of trilostane for the treatment of alopecia X in Alaskan malamutes

J Am Anim Hosp Assoc. 2005 Sep-Oct;41(5):336-42. doi: 10.5326/0410336.

Abstract

Three Alaskan malamutes with hair loss and slightly elevated blood concentrations of 17-hydroxyprogesterone after stimulation with adrenocorticotropic hormone (ACTH) were treated with trilostane. Trilostane, an inhibitor of 3 beta-hydroxysteroid dehydrogenase, was given twice daily at a dose of 3.0 to 3.6 mg/kg per day orally for 4 to 6 months. Routine ACTH stimulation tests were performed over 8 months to evaluate the degree of adrenal function suppression. Treatment with trilostane led to complete hair regrowth in all three dogs within 6 months. No adverse effects associated with trilostane were recognized.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 17-alpha-Hydroxyprogesterone / blood
  • 3-Hydroxysteroid Dehydrogenases / antagonists & inhibitors
  • Adrenocortical Hyperfunction / drug therapy
  • Adrenocortical Hyperfunction / enzymology
  • Adrenocortical Hyperfunction / veterinary*
  • Adrenocorticotropic Hormone
  • Alopecia / drug therapy
  • Alopecia / enzymology
  • Alopecia / veterinary*
  • Animals
  • Dihydrotestosterone / analogs & derivatives*
  • Dihydrotestosterone / therapeutic use
  • Dog Diseases / drug therapy*
  • Dog Diseases / enzymology
  • Dogs
  • Enzyme Inhibitors / therapeutic use*
  • Male
  • Treatment Outcome

Substances

  • Enzyme Inhibitors
  • Dihydrotestosterone
  • 17-alpha-Hydroxyprogesterone
  • Adrenocorticotropic Hormone
  • 3-Hydroxysteroid Dehydrogenases
  • trilostane